- Research article
- Open Access
Genomic analysis of microRNA time-course expression in liver of mice treated with genotoxic carcinogen N-ethyl-N-nitrosourea
© Li et al; licensee BioMed Central Ltd. 2010
- Received: 4 August 2010
- Accepted: 28 October 2010
- Published: 28 October 2010
Dysregulated expression of microRNAs (miRNAs) has been previously observed in human cancer tissues and shown promise in defining tumor status. However, there is little information as to if or when expression changes of miRNAs occur in normal tissues after carcinogen exposure.
To explore the possible time-course changes of miRNA expression induced by a carcinogen, we treated mice with one dose of 120 mg/kg N-ethyl-N-nitrosourea (ENU), a model genotoxic carcinogen, and vehicle control. The miRNA expression profiles were assessed in the mouse livers in a time-course design. miRNAs were isolated from the livers at days 1, 3, 7, 15, 30 and 120 after the treatment and their expression was determined using a miRNA PCR Array. Principal component analysis of the miRNA expression profiles showed that miRNA expression at post-treatment days (PTDs) 7 and 15 were different from those at the other time points and the control. The number of differentially expressed miRNAs (DEMs) changed over time (3, 5, 14, 32, 5 and 5 at PTDs 1, 3, 7, 15, 30 and 120, respectively). The magnitude of the expression change varied with time with the highest changes at PTDs 7 or 15 for most of the DEMs. In silico functional analysis of the DEMs at PTDs 7 and 15 indicated that the major functions of these ENU-induced DEMs were associated with DNA damage, DNA repair, apoptosis and other processes related to carcinogenesis.
Our results showed that many miRNAs changed their expression to respond the exposure of the genotoxic carcinogen ENU and the number and magnitude of the changes were highest at PTDs 7 to 15. Thus, one to two weeks after the exposure is the best time for miRNA expression sampling.
- miRNA Expression
- Ingenuity Pathway Analysis
- miRNA Expression Profile
- Carcinogen Exposure
- Genotoxic Carcinogen
MicroRNA (miRNA) is a class of small nucleic acids that negatively regulate gene expression . They are single-stranded RNA molecules that are not translated into proteins. Each miRNA molecule is partially complementary to one or more mRNA transcripts, and functions to down-regulate gene expression by inhibiting protein translation or destabilizing target transcripts . The expression of miRNAs is regulated developmentally and spatially, and is involved in differentiation and proliferation of cells . Therefore, miRNA molecules can modulate a wide array of growth and differentiation processes in cancer . A number of studies have demonstrated that miRNA expression is commonly dysregulated in human cancer; and that miRNAs are extensively involved in carcinogenesis and act as either dominant or recessive cancer genes . miRNA expression profiling has shown promise in defining tumor malignancy status and is surprisingly informative when used to identify tumor types, differentiation states and developmental lineages .
The available information on miRNA function suggests that miRNA expression profiles might also have predictive value for assessing chemical carcinogenicity. It has been reported that expression of some miRNAs is associated with tumor initiation . Thus, specific miRNAs could represent attractive molecules as informative biomarkers of exposure to carcinogens. Studies on the relationship between miRNAs and carcinogen exposure have been previously reported  and miRNA expression has been shown to be dysregulated by many carcinogenic agents like 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) , 7,12-dimethylbenz[a]anthrance , 2-acetylaminofluorene (2-AAF)  and radiation . The results of these studies indicate that miRNAs are involved in early stages of carcinogenesis and suggest that miRNAs could be a useful tool for detecting carcinogen exposure. Expression data from these studies, however, were generated primarily from chronic or subchronic carcinogen exposures in which the animals were treated with multiple doses of carcinogens over a long period such as 20 or 24 weeks [9, 11]. This kind of studies are able to reveal cumulative effects of chemical treatments on miRNA expression. However, they are unable to provide time course miRNA expression data caused by a single dose of chemical treatment.
Time-course data is an important component of toxicological studies. It reveals a toxicological response as a transient, continuous, or delayed response. Since the regulation of miRNA expression is a dynamic process, a temporal design provides information regarding an appropriate sampling time for miRNA expression change after carcinogen treatment. In this study, N-ethyl-N-nitrosourea (ENU), a model genotoxic carcinogen, is used for the carcinogen treatment. We treated mice with one dose of ENU and measured the expression level of miRNAs in the liver of the treated and control mice at several posttreatment times. This treatment and sampling design allowed us to analyze the time-course changes of miRNA expression in tissues exposed to the carcinogen. We have previously published the mutant frequency data from mice treated in this study 
ENU is mutagenic in a wide variety of mutagenicity test systems and carcinogenic in various organs of mammals . It induces hepatocellular carcinomas in mouse liver that receives a single dose of ENU . Thus, ENU is a suitable genotoxic carcinogen for studying the time course expression of miRNAs. Usually, biological effects of a carcinogen are affected by various factors, including chemical absorption, distribution, metabolism, and elimination. ENU, however, directly alkylates nucleotides without metabolic activation . Thus, choosing ENU as a model carcinogen avoids the effects of these unrelated processes to a large extent due to ENU's direct activity. Most importantly, abundant information on the time-course effects of ENU toxicity and carcinogenicity has been accumulated including data regarding DNA adducts , gene mutations , gene expression  and tumor formation . This information is valuable to understand alteration of miRNA expression induced by ENU exposure.
Principal component analysis
Time course analysis of miRNA expression
MicroRNAs whose expressions were significantly changed by ENU in at least one post-treatment time point.
Ectopic expression of let-7b reduced HMGA2 expression and cell proliferation in a lung cancer cell line .
miR-106b was up-regulated in several human tumors compared with adjacent normal tissues and formed a negative-feedback loop with cell cycle regulator E2F1 .
Expression of miR-130a was significantly up-regulated in primary glioblastomas compared with normal peripheral brain tissue .
miR-130b showed increased expression in patients with primary WHO grade II gliomas that spontaneously progressed to WHO grade IV secondary glioblastomas . miR-130b was also up-regulated in human T-cell leukemia virus 1 (HTLV-1)-mediated cellular transformation .
miR-135b expressed was increased in patients with post-surgery elevation of prostate-specific antigen (chemical relapse), as compared with patients with non-relapse disease .
miR-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines .
Introduction of miR-144 affected caspase activation in TRAIL-induced apoptosis pathway .
Control of B cell differentiation by targeting the transcription factor c-Myb .
miR-219 displayed dysregulated expression in human tongue carcinomas .
miR-222 was up-regulated in atypical teratoid-rhabdoid tumors .
miR-301a expression was significantly differentiated in smoker versus non-smoker .
- - -
- - -
Over-expression of miR-32 was associated with poor outcome of human kidney cancer .
miR-335 was highly expressed in pediatric acute myeloid leukemia .
+ + +
Regulation of p53-mediated apoptosis .
+ + +
+ + +
Induction of cell cycle arrest by joining p53 network .
Induction of cell cycle arrest by joining p53 network .
- - -
- - -
miR-369-5p was up-regulated in mesenchymal stem cells propagation .
miR-423-5p was involved in muscle development and growth and showed greatest in the neonate development stage .
miR-451 expression was up-regulated in multidrug resistant cancer cell lines .
A variant affecting miR-453's putative target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women .
miR-484 was involved in adrenal tumorigenesis .
+ + +
miR-590-3p and other miRNAs were suggested to mediate control of autoimmune gene expression .
miR-590 was involved in regulating the expression of transforming growth factor TGF-beta1 and its receptor TGF-betaRII .
miR-762 was up-regulated in tumor tissue induced by DMBA .
- - -
miR-93 was over-expressed in human T-cell leukemia virus 1- transformed human T-cell lines and primary peripheral blood mononuclear cells from adult T-cell leukemia patients .
miR-205 expression was down-regulated in breast cancer, but up-regulated in other types of cancer including lung cancer, bladder cancer and ovarian cancer .
miR-142-3p was over-expressed in childhood B-cell precursor acute lymphoblastic leukemia .
Confirmation of the temporal expression changes of three miR-34 family miRNAs and one miR-762 family miRNA by individual TaqMan assays
Hierarchical clustering analysis of the DEMs at different posttreatment times
In silico Functional analysis of the DEMs
A literature search of the PubMed database was conducted using the gene name of each DEM without considering species difference since miRNA functions are relatively conservative across different species . Twenty seven out of 43 of the DEMs have been functionally investigated by biological experiments (Table 1). Many of these miRNAs were dysregulated in tumors or tissues exposed to carcinogens. They played roles in cell proliferation, cell cycle regulation, cellular transformation, immune response, invasion, apoptosis, tissue development and growth. Some of the DEMs are putative tumor suppressors or oncogenes such as miR-34a (see literature cited in Table 1).
To explore the temporal response of miRNA to treatment of genotoxic carcinogens, mice were administrated with one dose of 120 mg/kg ENU, which can significantly induce tumors and mutations in mouse liver . The ENU treatment resulted in temporal changes in miRNA expression in mouse liver and the altered miRNAs are functionally related to the carcinogenicity and mutagenicity of ENU according to the in silico functional analysis of the DEMs.
Temporal changes in miRNA expression after ENU treatment
miRNA aberrant expression has been found to be a common feature of tumor malignancy . Several studies on carcinogen-altered miRNA expression have been conducted and showed that chronic or subchronic carcinogen exposure can dysregulate miRNA expression. Long-term exposure of female Fisher 344 (F344) rats to a tamoxifen-containing diet led to alterations in the miRNA expression profile in liver tissue prior to tumor formation . Sprague-Dawley rats treated with 2-AAF for 12 or 24 weeks exhibited disrupted regulation of the miR-34a-p53 feed-back loop and substantial deregulation of expression of miR-18, miR-21, miR-182, and miR-200 family miRNAs . Male F344 rats continuously fed with NNK for up to 20 weeks resulted in alteration of miRNA expression in the lungs of rats . Although these studies demonstrated that carcinogen exposures were able to alter expression of certain miRNAs, such experiments could not provide information on temporal response of miRNAs to carcinogen exposure. The alteration of miRNA expression by these subchronic to chronic treatments do not provide the response period of miRNAs to treatment. The changes could result from the cumulative effects of persistent long-term chemical exposure or from a short term response. At present, the duration of miRNA response to exposure to a genotoxic carcinogen in animals or humans is unknown. In this study, mice received only a single dose of a potent genotoxic carcinogen ENU and were sacrificed at different time points so that temporal response of miRNA expression to the treatment can be determined. The results clearly demonstrate that exposure of mice to a single dose of ENU can cause distinctive alterations in miRNA expression at the different sampling times after the ENU treatment (Table 1 and Figures 1, 2, 3 and 4).
Sampling time after the ENU exposure appears to be a very important parameter in miRNA expression in both the amount of DEMs and their fold-change levels. Principal component analysis indicates that mouse livers sampled at 7 and 15 days after ENU treatment display distinctive miRNA expression patterns compared to controls and other sampling time points (Figure 1). Three DEMs were found one day after the ENU treatment. The number of DEMs increased with the sampling time, reaching the peak at PTD 15 with 32 DEMs. The amount of DEMs declined after 15 days and only 5 DEMs were identified at PTDs 30 and 120 (Figure 2). The magnitude of the DEMs' expression alteration was also changed with time. Most of the DEMs had their highest fold-changes at PTDs 7 or 15 (Figures 4 and 5). Hierarchical clustering analysis of the DEMs divided them into four groups according to the change direction and intensity of these DEMs' expression alteration. The DEMs in Groups II and IV responded to the ENU exposure quickly, indicating that some miRNAs can be changed by the treatment within a few days. However, regarding the alteration of miRNA expression induced by the ENU treatment, both the amount and the change magnitude of the DEMs peaked at PTD 15.
The pattern of temporal changes in miRNA expression after ENU treatment is different from previous reports on gene expression changed by ENU treatment . In the previous studies, gene expression changes in both amount and intensity peaked at 4 hours and declined at 20 hours, 14 and 28 days after administration of ENU. The mechanism(s) for the difference between the temporal changes induced by ENU in miRNA expression and gene expression is unknown. It is possible that many genes, such as DNA repair genes, can directly respond to the DNA damage caused by ENU exposure whereas miRNAs as posttranscriptional regulators for gene expression may respond indirectly to ENU insults via the alteration of gene expression . Also, turnover rates for mature mRNAs and miRNAs could play a role in the difference. Mature miRNAs generally have lower turnover rates and exist longer than mRNAs .
The pattern of the temporal expression change could result from biological responses of liver miRNAs to the genotoxic and cytotoxic effects of ENU. miRNA expression may vary between different biological mechanisms like DNA adduct formation by ENU, cell death induced by the DNA damage, and cell proliferation due to the cell death. The DNA damage induced by ENU is very fast, occurring within hours after treatment . However, the DNA repair and cell proliferation processes could take a few weeks . Some miRNAs like miR-34a could respond to the DNA damage quickly and exhibited dysregulation within one day while most miRNAs that function mainly as regulators for cell differentiation and proliferation altered their expression only after several days.
In silico pathway analysis of the functions of the ENU-induced DEMs
ENU, as a potent monofunctional ethylating agent, reacts directly with the nucleophilic nitrogen and oxygen atoms in DNA and with the oxygen atoms in the backbone phosphates, forming various ethylated products including N7-ethylgunine, N3-ethyladenine, O6-ethylguanine, O2- and O4-ethylthymine, and O2-ethylcytosine [16, 25]. Once formed in the DNA, these products can result in cell death, like apoptosis  or become the substrate of cellular repair processes of various kinds, such as specific dealkylation by the O6- alkylguanine-DNA-alkyltransferase (AGT) , removal of N7-alkylguanine or N3-alkylguanine by specific glycosylases , or removal O4-alkylthymine by the more general action of the nucleotide excision repair system . Also, ENU is known to induce cell proliferation . If miRNAs are involved in the regulation of the genes that are related to genotoxic functions like cell proliferation, cell cycle arrest, apoptosis, and DNA repair, expression of miRNAs related to these functions should be changed by the ENU treatment. Indeed, our literature search results indicate that most of the DEMs induced by ENU treatment function as regulators for cell cycle arrest , cell proliferation , apoptosis , DNA repair  and other biological processes related to ENU cytotoxicity, genotoxicity and carcinogenicity (Table 1).
Because each miRNA can regulate many target genes and several miRNAs may affect a single gene, it is important to analyze the functions of all DEMs together. Computational approaches have been a major focus in determining the general principles that are thought to govern miRNA target recognition and mode of action. In this study, the target genes computationally predicted by the miRanda algorithm were used for functional analysis. The miRanda algorithm was developed by the Sanger Institute and is widely used in miRNA studies . The top 5% target genes of all of the DEMs were selected and used for IPA functional analysis. The top functions affected by the ENU exposure are tumor morphology, cell cycle, DNA replication, recombination and repair, and cancer. These biological functions identified by the analysis show that the DEMs are related to ENU-induced carcinogenesis (Figure 6). For example, many genes involved in DNA repair or response to DNA damage can be dysregulated by ENU treatment  and the miRNAs that target these genes could change their expression to regulate these functional processes.
MiR-34 family might have the potential to be explored as a biomarker for genotoxin exposure
Our results indicate that some miRNAs responded to ENU treatment with a wide temporal range. These miRNAs might have the potential to be used as biomarkers for predicting the genotoxic carcinogenicity of chemicals. Among these miRNAs, the miR-34 family is worth special attention. All of the 3 miRNAs were significantly changed at four different time points (Figure 3). Their expressions were enhanced by 3.21-fold (miR-34a), 3.11-fold (miR-34b) and 2.37-fold (miR-34c) on PTD 1 and the fold changes continued to increase and peaked at PTDs 7 or 15. The miR34 family genes are the direct transcription targets of tumor suppressor p 53 [32, 38]. miR-34b and miR-34c are encoded by the same primary transcript from chromosome 11 in human or chromosome 9 in mouse while miR-34a is located in a different chromosome . The promoter region of miR-34a and miR-34b/c each contain a palindromic sequence that matches the canonical p 53 binding site and can be bound by p 53 as shown by chromatin immunoprecipitation . Interestingly, our results found that miR-34b and miR-34c changed in correlated manner at all the sampling time points (Figure 3). miRNAs in miR-34 family play important roles in various p 53-initiated biological processes. Up-regulation of miR-34a and miR-34b/c caused a cell-cycle arrest in the G1 phase . miR-34b/c inhibits cell proliferation and colony formation in soft agar . Introduction of miR-34a and miR-34b/c into primary human diploid fibroblasts induces cellular senescence . Re-expression of miR-34a in tumor cells induced apoptosis . These biological processes controlled by miRNAs in the miR-34 family are related to ENU cytotoxicity, genotoxicity, and carcinogenicity. Our results indicate that the miR-34 family of miRNAs seems to have the potential to be valuable biomarkers for toxicological application.
Our study indicates that one dose treatment of ENU, a chemical inducing tumors and mutations, resulted in deregulation of a large number of miRNAs. In silico functional analysis suggested that these miRNAs were related to ENU mutagenesis and carcinogenesis in the mouse liver. The deregulation of ENU-induced miRNA expression changed with time and peaked at day 15 after the treatment. The findings suggest that one to two weeks after ENU exposure is the best time for miRNA expression sampling. Moreover, miRNAs in the miR-34 family worth further study to explore their potential as biomarkers for exposure of genotoxic carcinogens.
The animal treatment protocol and mutant frequency analysis was described previously . Briefly, six-month-old female Big Blue mice were injected intraperitoneally with a single dose of 120 mg/kg body weight ENU (CAS# 759-73-9, Sigma, St. Louis, MO) or the vehicle dimethylsulfoxide (DMSO, Sigma) in 1 ml/kg body weight (0.1%). For ENU treatment, groups of 4 or 5 animals were sacrificed on PTDs 1, 3, 7, 15, 30, and 120. For the vehicle treatment, 4 and 3 animals were sacrificed on PTDs 1 and 30, respectively. DMSO is not carcinogenic and mutagenic . It has showed no effects on gene expression in the dose that we used . Also, our previous study demonstrated that DMSO did not change mutant frequency in mouse liver at different sampling times . Therefore, the 7 control samples were grouped together as a common control group for the treatment groups sampling at the different time points to increase the statistical power. The tissues were isolated and frozen at -80°C. The liver samples were used for this study. All animal experiments were conducted by following the recommendations set forth by our Institutional Animal Care and Use Committee.
About 60 mg of liver tissue was cut from each frozen liver sample and suspended in RNAlater-ICE (Ambion Inc., Austin, TX). The tissue pieces were transferred to 600 μl RNA lysis/binding buffer and minced using Tissue Tearor™ (BioSpec Products Inc., Bartlesville, OK). miRNAs were isolated using mirVana™ miRNA isolation kit (Ambion) that specifically captures small RNAs with length of less than 200 nucleotides. The isolated RNAs were resolved in 100 μl nuclease-free water (Ambion). RNA concentrations were determined using NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, Wilmington, Delaware). The quality of RNA samples was characterized on an Agilent BioAnalyzer (Agilent Technologies, Santa Clara, CA) using an RNA6000 Nano Chip (Agilent).
PCR Array analysis of miRNA expression
Two hundred nanograms of enriched small RNA were converted into cDNA using RT2 miRNA First Strand Kit (SABiosciences Corporation, Frederick, MD). The cDNAs were mixed with 2 × RT2 SYBR Green PCR Master Mix (SABiosciences) and dispersed into 384-well Mouse Genome miRNA PCR Array (MAM-3100E, SABiosciences) with 10 μl/well reaction volume. The PCR array contained a panel of primer sets for 376 mouse miRNAs, four small RNAs as the internal controls and four quality controls. The real-time qRT-PCR was performed on a 7900 real-time PCR system (Applied Biosystems Inc., Foster, CA) with following cycling parameters: 95°C for 10 mins, then 40 cycles of 95°C for 15 s, 60°C for 30 s and 72°C for 30 s. SYBR Green fluorescence was recorded from every well during the annealing step of each cycle. The threshold cycle (Ct) value of each sample was calculated with software SDS 2.3 (Applied Biosystems). To calculate Cts, we set the threshold line as 0.15 and kept it the same across all of the analyses. The baseline was automatically defined by the software.
Normalization and statistical analysis
Normalization and statistical analysis of miRNA expression were conducted using SABiosciences Online PCR Array Data Analysis Web Portal. MiRNA expressions were compared between the treatment group at each time point and the control group. The ΔΔCt method was utilized to calculate the fold change (FC). Four genes, snoRNA251, snoRNA202, snoRNA142, and U6 in the PCR arrays, were averaged as the endogenous control and the vehicle control group was used as external control to normalize each sample. The formula: FC = 2^ [-(mean of ΔCt values of treated samples - mean of ΔCt values of control samples)] was used for up-regulated gene, while FC = - 2^ (mean of ΔCt values of treated samples - mean of ΔCt values of control samples) was used for the down-regulations. T-tests were used to calculate the p value to determine whether there is a significant difference for miRNA expression between the control and the treatment groups for each miRNA at each time point. miRNAs with p < 0.01 and the absolute value of FC >2.0 were considered as DEMs.
Principal component analysis and hierarchical clustering analysis
Principal component analysis of expression profiles of all miRNAs from each time point after the ENU treatment was conducted using the autoscaled method within ArrayTrack . The normalized ΔCt values were used for this analysis and the analysis was performed without filtering any miRNAs.
To examine types of expression changes, hierarchical clustering analysis was performed using R software http://www.r-project.org/. The miRNAs whose expressions were significantly differentially expressed at least at one sampling time were used for the clustering. The FCs for control samples were set to zero. Euclidean and Wards methods were used for distance-calculation and linkage, respectively.
In silico Functional analysis of the DEMs
The miRanda database was used for identification of DEMs' target genes http://microrna.sanger.ac.uk/sequences/. The top 5% of the most reliable predicted target genes of the DEMs at PTDs 7 and 15 were selected according to the p values given in the database. A total of 1376 genes were determined as the predictive target genes of these DEMs. The selected target genes were then input into Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Inc., Redwood City, CA). Ingenuity Core Analysis and Knowledge Base was used as the reference set. IPA interpreted the genes in the context of biological processes, pathways and molecular networks and defined the most relevant biological functions of the predicted genes of the DEMs.
TaqMan qPCR confirmation of the temporal expression changes of miR-34 family miRNAs
TaqMan MicroRNA Assays were used to confirm the temporal expression changes of 3 miR-34 family members, mmu-miR-34a, mmu-miR-34b-5p, and mmu-miR-34c, as well as a miR-762 family member, mmu-miR-762. The experiment also severed as the verification of the RT2-mouse miRNA PCR array assay. The TaqMan miRNA assay kits were purchased from Applied Biosystems (Foster City, CA). The same small RNA samples used for the PCR arrays were also used for the TaqMan miRNA assays. The experiment was performed by following the manufacturer's protocol. In brief, each 10 μl reverse transcription (RT) reaction contained 44 ng of small RNA, 50 nM stem-loop RT primer, 1 × RT buffer, 0.25 mM each of dNTPs, 3.33 U/μl MultiScribe™ reverse transcriptase and 0.25 U/μl RNase inhibitor. The RT reactions were incubated in a GeneAmp PCR System 9700 (Applied Biosystems) for 30 min at 16°C, 30 min at 42°C, followed by 5 min at 85°C, and then held at 4°C. Each real-time PCR reaction (10 μl volume) containing 0.78 μl of RT product, 5 μl of 2× TaqMan Universal PCR Master Mix, and 0.5 μl TaqMan MicroRNA assay (the mixture of TaqMan probe, forward primer, and reverse primer). The PCR reaction was conducted in an Applied Biosystems 7500 Fast Real-Time PCR System at 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. The threshold cycle (Ct) is defined as the fractional cycle number at which the fluorescence exceeds the fixed threshold of 0.02. Four samples at each time point were used for the TaqMan confirmation.
All PCR array Ct raw data are available through Gene Expression Omnibus (Series accession numbers: GSE20248).
This research was supported by an appointment (Z. Li) to the Postgraduate Research Program at the NCTR administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and the US Food and Drug Administration. We would like to thank Drs. Tao Han and Joshua Kwekel for their enlightening comments and hearty discussions in reviewing the manuscript.
The views presented in this article do not necessarily reflect those of the Food and Drug Administration.
- Ambros V: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003, 113 (6): 673-676. 10.1016/S0092-8674(03)00428-8.PubMedView ArticleGoogle Scholar
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116 (2): 281-297. 10.1016/S0092-8674(04)00045-5.PubMedView ArticleGoogle Scholar
- Shivdasani RA: MicroRNAs: regulators of gene expression and cell differentiation. Blood. 2006, 108 (12): 3646-3653. 10.1182/blood-2006-01-030015.PubMed CentralPubMedView ArticleGoogle Scholar
- Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA: Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 2007, 7 (7): 1009-1019. 10.1517/147125188.8.131.529.PubMedView ArticleGoogle Scholar
- Cummins JM, Velculescu VE: Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006, 25 (46): 6220-6227. 10.1038/sj.onc.1209914.PubMedView ArticleGoogle Scholar
- Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, et al: A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005, 353 (17): 1793-1801. 10.1056/NEJMoa050995.PubMedView ArticleGoogle Scholar
- Hagan JP, Croce CM: MicroRNAs in carcinogenesis. Cytogenet Genome Res. 2007, 118 (2-4): 252-259. 10.1159/000108308.PubMedView ArticleGoogle Scholar
- Chen T: The role of MicroRNA in Chemical Carcinogenesis. Journal of Environmental Science and Health Part C-Environmental Carcinogenesis & Ecotoxicology Reviews. 2010, 28: 89-124.View ArticleGoogle Scholar
- Kalscheuer S, Zhang X, Zeng Y, Upadhyaya P: Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis. 2008, 29 (12): 2394-2399. 10.1093/carcin/bgn209.PubMed CentralPubMedView ArticleGoogle Scholar
- Yu T, Wang XY, Gong RG, Li A, Yang S, Cao YT, Wen YM, Wang CM, Yi XZ: The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. J Exp Clin Cancer Res. 2009, 28: 64-10.1186/1756-9966-28-64.PubMed CentralPubMedView ArticleGoogle Scholar
- Pogribny IP, Muskhelishvili L, Tryndyak VP, Beland FA: The tumor-promoting activity of 2-acetylaminofluorene is associated with disruption of the p53 signaling pathway and the balance between apoptosis and cell proliferation. Toxicol Appl Pharmacol. 2009, 235 (3): 305-311. 10.1016/j.taap.2008.12.021.PubMedView ArticleGoogle Scholar
- Ilnytskyy Y, Zemp FJ, Koturbash I, Kovalchuk O: Altered microRNA expression patterns in irradiated hematopoietic tissues suggest a sex-specific protective mechanism. Biochem Biophys Res Commun. 2008, 377 (1): 41-45. 10.1016/j.bbrc.2008.09.080.PubMedView ArticleGoogle Scholar
- Wang J, Liu X, Heflich RH, Chen T: Time course of cII gene mutant manifestation in the liver, spleen, and bone marrow of N-ethyl-N-nitrosourea-treated Big Blue transgenic mice. Toxicol Sci. 2004, 82 (1): 124-128. 10.1093/toxsci/kfh234.PubMedView ArticleGoogle Scholar
- Shibuya T, Morimoto K: A review of the genotoxicity of 1-ethyl-1-nitrosourea. Mutat Res. 1993, 297 (1): 3-38.PubMedView ArticleGoogle Scholar
- Kyriazis AP, Vesselinovitch SD: Transplantability and biological behavior of mouse liver tumors induced by ethylnitrosourea. Cancer Res. 1973, 33 (2): 332-338.PubMedGoogle Scholar
- Den Engelse L, De Graaf A, De Brij RJ, Menkveld GJ: O2- and O4-ethylthymine and the ethylphosphotriester dTp(Et)dT are highly persistent DNA modifications in slowly dividing tissues of the ethylnitrosourea-treated rat. Carcinogenesis. 1987, 8 (6): 751-757. 10.1093/carcin/8.6.751.PubMedView ArticleGoogle Scholar
- Watanabe T, Tanaka G, Hamada S, Namiki C, Suzuki T, Nakajima M, Furihata C: Dose-dependent alterations in gene expression in mouse liver induced by diethylnitrosamine and ethylnitrosourea and determined by quantitative real-time PCR. Mutat Res. 2009, 673 (1): 9-20.PubMedView ArticleGoogle Scholar
- Vesselinovitch SD, Rao KV, Mihailovich N, Rice JM, Lombard LS: Development of broad spectrum of tumors by ethylnitrosourea in mice and the modifying role of age, sex, and strain. Cancer Res. 1974, 34 (10): 2530-2538.PubMedGoogle Scholar
- Chen K, Rajewsky N: Deep conservation of microRNA-target relationships and 3'UTR motifs in vertebrates, flies, and nematodes. Cold Spring Harb Symp Quant Biol. 2006, 71: 149-156. 10.1101/sqb.2006.71.039.PubMedView ArticleGoogle Scholar
- Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, et al: Combinatorial microRNA target predictions. Nat Genet. 2005, 37 (5): 495-500. 10.1038/ng1536.PubMedView ArticleGoogle Scholar
- Ventura A, Jacks T: MicroRNAs and cancer: short RNAs go a long way. Cell. 2009, 136 (4): 586-591. 10.1016/j.cell.2009.02.005.PubMed CentralPubMedView ArticleGoogle Scholar
- Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O: Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res. 2007, 619 (1-2): 30-37.PubMedView ArticleGoogle Scholar
- Chen PY, Meister G: microRNA-guided posttranscriptional gene regulation. Biol Chem. 2005, 386 (12): 1205-1218. 10.1515/BC.2005.139.PubMedView ArticleGoogle Scholar
- Kai ZS, Pasquinelli AE: MicroRNA assassins: factors that regulate the disappearance of miRNAs. Nat Struct Mol Biol. 2010, 17 (1): 5-10. 10.1038/nsmb.1762.PubMedView ArticleGoogle Scholar
- Goth R, Rajewsky MF: Ethylation of nucleic acids by ethylnitrosourea-1- 14 C in the fetal and adult rat. Cancer Res. 1972, 32 (7): 1501-1505.PubMedGoogle Scholar
- Jansen JG, de Groot AJ, van Teijlingen CM, Lohman PH, Mohn GR, Vrieling H, van Zeeland AA: Formation and persistence of DNA adducts in pouch skin fibroblasts and liver tissue of rats exposed in vivo to the monofunctional alkylating agents N-methyl-N-nitrosourea or N-ethyl-N-nitrosourea. Mutat Res. 1994, 307 (1): 95-105.PubMedView ArticleGoogle Scholar
- Morris SM, McGarrity LJ, Domon OE, Chen JJ, Hinson WG, Bucci TJ, Warbritton AR, Casciano DA: The role of programmed cell death in the toxicity of the mutagens, ethyl methanesulfonate and N-ethyl-N'-nitrosourea, in AHH-1 human lymphoblastoid cells. Mutat Res. 1994, 306 (1): 19-34.PubMedView ArticleGoogle Scholar
- Pegg AE, Wiest L, Foote RS, Mitra S, Perry W: Purification and properties of O6-methylguanine-DNA transmethylase from rat liver. J Biol Chem. 1983, 258 (4): 2327-2333.PubMedGoogle Scholar
- Ibeanu G, Hartenstein B, Dunn WC, Chang LY, Hofmann E, Coquerelle T, Mitra S, Kaina B: Overexpression of human DNA repair protein N-methylpurine-DNA glycosylase results in the increased removal of N-methylpurines in DNA without a concomitant increase in resistance to alkylating agents in Chinese hamster ovary cells. Carcinogenesis. 1992, 13 (11): 1989-1995. 10.1093/carcin/13.11.1989.PubMedView ArticleGoogle Scholar
- Klein JC, Bleeker MJ, Roelen HC, Rafferty JA, Margison GP, Brugghe HF, van den Elst H, van der Marel GA, van Boom JH, Kriek E, et al: Role of nucleotide excision repair in processing of O4-alkylthymines in human cells. J Biol Chem. 1994, 269 (41): 25521-25528.PubMedGoogle Scholar
- Ying TS, Sarma DS, Farber E: Role of acute hepatic necrosis in the induction of early steps in liver carcinogenesis by diethylnitrosamine. Cancer Res. 1981, 41 (6): 2096-2102.PubMedGoogle Scholar
- Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007, 26 (5): 731-743. 10.1016/j.molcel.2007.05.017.PubMedView ArticleGoogle Scholar
- Lee YS, Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007, 21 (9): 1025-1030. 10.1101/gad.1540407.PubMed CentralPubMedView ArticleGoogle Scholar
- Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X: MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett. 2009, 286 (2): 217-222. 10.1016/j.canlet.2009.05.030.PubMed CentralPubMedView ArticleGoogle Scholar
- He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al: A microRNA component of the p53 tumour suppressor network. Nature. 2007, 447 (7148): 1130-1134. 10.1038/nature05939.PubMed CentralPubMedView ArticleGoogle Scholar
- Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res. 2008, 36 (Database issue): D154-158.PubMed CentralPubMedGoogle Scholar
- Stojic L, Brun R, Jiricny J: Mismatch repair and DNA damage signalling. DNA Repair (Amst). 2004, 3 (8-9): 1091-1101. 10.1016/j.dnarep.2004.06.006.View ArticleGoogle Scholar
- Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007, 26 (5): 745-752. 10.1016/j.molcel.2007.05.010.PubMed CentralPubMedView ArticleGoogle Scholar
- Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY: MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007, 67 (18): 8433-8438. 10.1158/0008-5472.CAN-07-1585.PubMedView ArticleGoogle Scholar
- Zeiger E, Anderson B, Haworth S, Lawlor T, Mortelmans K: Salmonella mutagenicity tests: V. Results from the testing of 311 chemicals. Environ Mol Mutagen. 1992, 19 (Suppl 21): 2-141. 10.1002/em.2850190603.PubMedView ArticleGoogle Scholar
- Hamatani T, Carter MG, Sharov AA, Ko MS: Dynamics of global gene expression changes during mouse preimplantation development. Dev Cell. 2004, 6 (1): 117-131. 10.1016/S1534-5807(03)00373-3.PubMedView ArticleGoogle Scholar
- Tong W, Harris S, Cao X, Fang H, Shi L, Sun H, Fuscoe J, Harris A, Hong H, Xie Q, et al: Development of public toxicogenomics software for microarray data management and analysis. Mutat Res. 2004, 549 (1-2): 241-253.PubMedView ArticleGoogle Scholar
- Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, et al: E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008, 13 (3): 272-286. 10.1016/j.ccr.2008.02.013.PubMedView ArticleGoogle Scholar
- Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 2005, 334 (4): 1351-1358. 10.1016/j.bbrc.2005.07.030.PubMedView ArticleGoogle Scholar
- Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE, Reifenberger G: Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas. Brain Pathol. 2010, 20 (3): 539-550. 10.1111/j.1750-3639.2009.00328.x.PubMedView ArticleGoogle Scholar
- Yeung ML, Yasunaga J, Bennasser Y, Dusetti N, Harris D, Ahmad N, Matsuoka M, Jeang KT: Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res. 2008, 68 (21): 8976-8985. 10.1158/0008-5472.CAN-08-0769.PubMed CentralPubMedView ArticleGoogle Scholar
- Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2009, 16 (3): 206-216.PubMedGoogle Scholar
- Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D: Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 2007, 67 (22): 10782-10788. 10.1158/0008-5472.CAN-07-1484.PubMedView ArticleGoogle Scholar
- Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, Rajewsky K: MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007, 131 (1): 146-159. 10.1016/j.cell.2007.07.021.PubMedView ArticleGoogle Scholar
- Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI: Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 2008, 14 (9): 2588-2592. 10.1158/1078-0432.CCR-07-0666.PubMedView ArticleGoogle Scholar
- Sredni ST, Bonaldo MD, Costa FF, Huang CC, Hamm CA, Rajaram V, Tomita T, Goldman S, Bischof JM, Soares MB: Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. Childs Nerv Syst. 2010, 26 (3): 279-83. 10.1007/s00381-009-1028-y.PubMedView ArticleGoogle Scholar
- Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S: CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosomes Cancer. 2009, 48 (7): 615-623. 10.1002/gcc.20669.PubMedView ArticleGoogle Scholar
- Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT: MicroRNA profiling of human kidney cancer subtypes. Int J Oncol. 2009, 35 (1): 109-114. 10.3892/ijo_00000318.PubMedView ArticleGoogle Scholar
- Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009, 4 (11): e7826-10.1371/journal.pone.0007826.PubMed CentralPubMedView ArticleGoogle Scholar
- Li Z, Lu J, Xu P, Xie X, Chen L, Xu T: Mapping the interacting domains of STIM1 and Orai1 in Ca2 + release-activated Ca2 + channel activation. J Biol Chem. 2007, 282 (40): 29448-29456. 10.1074/jbc.M703573200.PubMedView ArticleGoogle Scholar
- Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, Benes V, Blake J, Pfister S, Eckstein V, et al: Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS One. 2008, 3 (5): e2213-10.1371/journal.pone.0002213.PubMed CentralPubMedView ArticleGoogle Scholar
- McDaneld TG, Smith TP, Doumit ME, Miles JR, Coutinho LL, Sonstegard TS, Matukumalli LK, Nonneman DJ, Wiedmann RT: MicroRNA transcriptome profiles during swine skeletal muscle development. BMC Genomics. 2009, 10: 77-10.1186/1471-2164-10-77.PubMed CentralPubMedView ArticleGoogle Scholar
- Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008, 76 (5): 582-588. 10.1016/j.bcp.2008.06.007.PubMed CentralPubMedView ArticleGoogle Scholar
- Tchatchou S, Jung A, Hemminki K, Sutter C, Wappenschmidt B, Bugert P, Weber BH, Niederacher D, Arnold N, Varon-Mateeva R, et al: A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis. 2009, 30 (1): 59-64. 10.1093/carcin/bgn253.PubMedView ArticleGoogle Scholar
- Bimpaki EI, Iliopoulos D, Moraitis A, Stratakis CA: MicroRNA signature in massive macronodular adrenocortical disease and implications for adrenocortical tumorigenesis. Clin Endocrinol (Oxf). 2010, 72 (6): 744-51. 10.1111/j.1365-2265.2009.03725.x.View ArticleGoogle Scholar
- Vinuesa CG, Rigby RJ, Yu D: Logic and extent of miRNA-mediated control of autoimmune gene expression. Int Rev Immunol. 2009, 28 (3-4): 112-138. 10.1080/08830180902934909.PubMedView ArticleGoogle Scholar
- Shan H, Zhang Y, Lu Y, Pan Z, Cai B, Wang N, Li X, Feng T, Hong Y, Yang B: Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res. 2009, 83 (3): 465-472. 10.1093/cvr/cvp130.PubMedView ArticleGoogle Scholar
- Wu H, Mo YY: Targeting miR-205 in breast cancer. Expert Opin Ther Targets. 2009, 13 (12): 1439-1448. 10.1517/14728220903338777.PubMedView ArticleGoogle Scholar
- Ju X, Li D, Shi Q, Hou H, Sun N, Shen B: Differential microRNA expression in childhood B-cell precursor acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2009, 26 (1): 1-10. 10.1080/08880010802378338.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.